ABSTRACT

Patients with cancer are at high risk to develop venous thromboembolism, and they are also more likely to develop complications from anticoagulant treatment. Because little research has focused on the oncology population to date, the optimal methods of prophylaxis and treatment remain uncertain in some clinical situations. Currently, low molecular weight heparin and warfarin are the most frequently used pharmacologic agents; however, they have their limitations. Other therapeutic options, such as inferior caval filters, are poorly studied and remain controversial. A summary of the most recent evidence on the prevention and treatment of venous thromboembolism in cancer patients is presented here.

KEY WORDS

Neoplasm, deep vein thrombosis, thromboembolism, prophylaxis, low molecular weight heparin, heparin, warfarin

1. INTRODUCTION

It is well established that cancer patients are at an increased risk of venous thromboembolism (VTE). In fact, the presence of malignancy increases the risk of VTE by a factor of 4 to 6, and large population-based studies show that the incidence of VTE is on the rise. Overall, cancer patients constitute 15%–20% of the patients diagnosed with VTE, and depending on the type of tumor, extent of malignancy, type of cancer treatment, and presence of other risk factors, 1%–25% of patients with malignancy will develop thrombosis.

Furthermore, cancer-associated thrombosis is linked with poor prognosis, and it is the second leading cause of death in cancer patients. In one study of a population registry, the 1-year survival of cancer patients diagnosed with VTE was one third that of cancer patients without VTE (12% vs. 36%) matched for sex, age, tumor type, and duration of the cancer. In another population-based study, the in-hospital mortality for cancer patients who developed VTE while in hospital was double that for patients who did not develop the complication.

This increase in mortality is partly attributable to fatal pulmonary embolism, but it also reflects the advanced stages of cancer and underlying aggressive tumor biology in these patients.

Cancer patients are also prone to adverse effects and failure of anticoagulant therapy. In comparison with patients without cancer, patients with cancer who are receiving warfarin experience 2 to 6 times more major bleeding episodes and 2 to 3 times more VTE recurrences. Based on prospective studies, the annual risk of recurrent VTE is 21%–27% and the annual risk of major bleeding is 12%–13%.

Primary prevention is the most effective way to reduce the morbidity and mortality associated with cancer-associated thrombosis, but surveys and registries consistently report the failure of physicians to comply with established guidelines leading to underutilization of primary prophylaxis in oncology patients. Given the impact that VTE has on this high-risk population, an increased focus on identifying optimal methods to prevent and treat VTE in patients with malignancy is needed. Current management strategies, and the evidence supporting them, are presented here.

2. PRIMARY PREVENTION: SURGICAL SETTINGS

The risk of VTE in cancer patients undergoing surgery has been estimated to be as high as 50% without prophylaxis. The exact risk varies with the type of surgery, but anticoagulants are generally effective in reducing the risk by 50%–80%. Tables I to III summarize the results from randomized controlled trials evaluating the efficacy and safety of anticoagulant prophylaxis in various oncologic surgery settings.

2.1 Major Abdominal and Pelvic Surgery

After major abdominal or pelvic cancer surgery, pharmacologic intervention with anticoagulants for 7–14 days postoperatively can reduce the risk of VTE to 1.3% for symptomatic deep vein thrombosis (DVT) and 0.4% for fatal pulmonary embolism. However, these numbers still represent a doubling or tripling of the risk.
### TABLE I  Randomized controlled trials for primary prophylaxis in cancer-related major abdominal and pelvic surgery

| Trial                          | Surgical setting          | Cancer patients (n) | Regimen Study | Regimen Control | Duration of treatment | Outcome                  | Incidences |
|-------------------------------|---------------------------|---------------------|----------------|------------------|-----------------------|--------------------------|------------|
| Enoxacon Study Group, 1997    | Abdominal and pelvic      | 631                 | Enoxaparin 40 mg daily | UFH 5000 IU 3 times daily | 10 Days               | VTE on bilateral venography or pulmonary scintigraphy | 14.7       |
| McLeod et al., 2001           | Colorectal                | 324                 | Enoxaparin 40 mg daily | UFH 5000 IU 3 times daily | Up to 10 days          | PE, venographic DVT at postoperative days 5, 9 | 13.9       |
| Agnelli et al., 2005          | Major abdominal           | 1941                | Fondaparinux 2.5 mg daily | Dalteparin 5000 IU daily | 5–9 Days              | Venographic DVT or PE up to postoperative day 10 | 4.7        |
| Bergqvist et al., 2002        | Abdominal and pelvic      | 332                 | Enoxaparin 40 mg daily | Enoxaparin 40 mg daily | 27–31 Days (study) 6–10 Days (control) | Bilateral venography between days 25 and 31 | 4.8        |
| Rasmussen et al., 2006        | Major abdominal           | 198                 | Dalteparin 5000 IU daily | Dalteparin 5000 IU daily | 28 Days (study) 7 Days (control) | Venographic VTE on postoperative days 7–28 | 8.8        |

* Results for the overall study population, including cancer and noncancer patients.

VTE = venous thromboembolism; UFH = unfractionated heparin; PE = pulmonary embolism; DVT = deep vein thrombosis.

### TABLE II  Randomized controlled trials for primary prophylaxis in cancer-related neurosurgery

| Trial                          | Surgical setting          | Patients (n) | Regimen Study | Regimen Control | Duration of treatment | Outcome                  | Incidences |
|-------------------------------|---------------------------|--------------|----------------|------------------|-----------------------|--------------------------|------------|
| Nurmohamed et al., 1996       | Craniotomy or spinal surgery for tumour or injury | 485          | Nadroparin 7500 IU daily and GCS | Placebo and GCS | 10 Days or until discharge | Venographic VTE at day 10 | 18.7       |
| Agnelli et al., 1998          | Elective cranial or spinal surgery for tumours | 307          | Enoxaparin 40 mg daily and GCS | Placebo and GCS | At least 7 days          | Venographic VTE at day 8, or PE | 17         |
| Goldhaber et al., 2002        | Craniotomy for brain tumour | 150          | Enoxaparin 40 mg daily and GCS and IPC | UFH 5000 IU twice daily and GCS and IPC | Until VTE or discharge | Ultrasonographic VTE at discharge | 12         |
| Macdonald et al., 2003        | Craniotomy               | 100          | Dalteparin 2500 IU daily and IPC | UFH 5000 IU twice daily and IPC | 7 Days, or until ambulating | PE, or ultrasonographic VTE at 1 month | 4          |

VTE = venous thromboembolism; GCS = graduated compression stockings; DVT = deep vein thrombosis; PE = pulmonary embolism; IPC = intermittent pneumatic compression; UFH = unfractionated heparin.
| Trial                        | Patients (n) | Study | Regimen                  | Duration of treatment | Outcome                  | Incidences     | Major bleeding (p Value) |
|-----------------------------|--------------|-------|--------------------------|-----------------------|--------------------------|----------------|-------------------------|
| Heilmann et al., 1989 19    | 300          | LMWH  | UFH 5000 IU 3 times daily | 7 Days                | PE, DVT by impedance    | 1.3 4.0 >0.05 | No significant difference in clinical and laboratory measures, specific incidence of major bleeding not cited |
| Clarke–Pearson et al., 1990 20 | 200          | UFH 5000 IU every 8 hours pre- and postoperatively | No prophylaxis until discharge | PE, DVT by 125I-labelled fibrinogen scan, impedance plethysmography to day 30 | 6.2 18.4 0.008 | No significant difference in clinical and laboratory measures, specific incidence of major bleeding not cited |
| Fricker et al., 1988 21     | 80           | Dalteparin 2500 IU 2 hours preoperatively and at 12 hours, then 5000 IU daily | UFH 5000 IU 2 hours preoperatively, then 3 times daily | PE, DVT by 125I-labelled fibrinogen scan, venography to 4 weeks | 0 2.5 >0.05 5.1 2.5 >0.05 | No significant difference in clinical and laboratory measures, specific incidence of major bleeding not cited |
| Von Tempelhoff et al., 1997 22 | 60           | LMWH  | UFH 5000 IU 3 times daily | 7 Days                | PE or scintigraphy, DVT by impedance plethysmography, venography, up to day 30 | 6.7 0 >0.05 | Not assessed |
| Heilmann et al., 1998 23    | 324          | Certoparin 3000 IU daily | UFH 5000 IU 3 times daily | 7 Days                | DVT by impedance plethysmography, venography up to day 10 | 6.3 6.1 1.0 16.8 28.7 0.01 |

VTE = venous thromboembolism; LMWH = low molecular weight heparin; UFH = unfractionated heparin; PE = pulmonary embolism; DVT = deep vein thrombosis.
as compared with patients without malignancy. Of the agents available for thromboprophylaxis, low molecular weight heparins (LMWHs) provide the most convenient, efficacious, and safe option. Compared with LMWHs, unfractionated heparin requires 3-times-daily injection and has a higher risk of heparin-induced thrombocytopenia. And although fondaparinux appears to be comparable to LMWH in efficacy and safety, limited data are available for it in the cancer setting, and a specific antidote for it is lacking. A post hoc subgroup analysis of cancer patients in a randomized trial found a lower risk of VTE with fondaparinux than with dalteparin, but that finding requires confirmation in future studies.

However, as hospital stays have shortened, the duration of prophylaxis may be inadequate for some patients. Cancer patients are at particularly high risk, considering that many of them undergo extensive surgery and require prolonged periods of recovery. In a prospective cohort study in which 2373 cancer patients were followed for a minimum of 30 days after surgery, 40% of symptomatic VTE occurred more than 3 weeks postoperatively, and 46% of deaths were the result of fatal pulmonary embolism. Clinical factors found to be associated with a higher risk of VTE were previous history of VTE [odds ratio (OR): 6.0], anesthesia lasting 2 hours or longer (OR: 4.5), bed rest for 4 days or longer (OR: 4.4), an advanced stage of cancer (OR: 2.7), and age 60 years or older (OR: 2.6).

Randomized controlled trials have shown that continuing prophylaxis with a LMWH up to 30 days postoperatively can reduce the risk of VTE by 60% without increasing the risk of bleeding. Based on these and other supportive studies, it is reasonable to prescribe extended prophylaxis in patients with one or more risk factors for VTE.

2.2 Neurosurgery

Neurosurgical patients present a challenging prophylaxis problem because of the underlying concern of intracerebral hemorrhage combined with a high incidence of VTE. In fact, craniotomy for brain neoplasm carries a VTE risk of 60% in the postoperative period and 23% at 1 year. This risk can be reduced by 40% with the use of LMWH prophylaxis starting 24 hours postoperatively. The risk of major bleeding, including intracranial hemorrhage, is less than 3%, but that risk is increased if LMWH prophylaxis is administered preoperatively. However, given the devastating consequences of an intracranial hemorrhage, most neurosurgeons prefer to use mechanical compression devices in the early operative period and to start pharmacologic prophylaxis when patients are more stable.

2.4 Gynecologic Surgery

Compared with the previous two groups, women undergoing gynecologic cancer surgery have a lower risk of VTE—about 2%. But that level of risk represents an increase by a factor of 5 over the risk in women having surgery for benign gynecologic problems. As with abdominal and pelvic surgery, unfractionated heparin and LMWH are both equally effective and safe in preventing DVT in this setting. Mechanical devices have also been shown to be effective.

2.5 Other Surgeries

There is a paucity of research on the risk of VTE and on its prevention in other surgical settings. Based on limited data and extrapolation from other surgical groups, unfractionated heparin and LMWH both appear relatively safe and effective, but solid evidence is lacking.

2.6 Mechanical Prophylaxis in Surgical Settings

As shown in one meta-analysis, compression stockings are effective in reducing the risk of VTE by two thirds in patients at moderate risk. Pneumatic compression devices are also effective, but they are cumbersome and interfere with mobilization. Also, they are more likely than pharmacologic prophylaxis to fail in high-risk groups. Compression devices are therefore currently reserved for situations in which anticoagulation is contraindicated. These devices are most effective when applied intraoperatively or immediately after surgery. Whether mechanical methods in combination with anticoagulants result in additional risk reduction is not clear.

2.7 Summary: Surgical Settings

Good evidence supports the routine use of postoperative thromboprophylaxis in patients undergoing surgery for cancer. That finding is endorsed by international and national consensus guidelines, including those from the American College of Chest Physicians (ACCP), the American Society of Clinical Oncology (ASCO), and the Italian Association of Medical Oncology (AIOM). Unfractionated heparin and LMWH are equally effective in preventing VTE and have a comparable risk for bleeding. Less experience and data are available for fondaparinux. Extended prophylaxis should be strongly considered in patients with additional risk factors for VTE. In those patients who have a contraindication for anticoagulation, mechanical methods are reasonable substitutes.

3. PRIMARY PREVENTION: MEDICAL SETTINGS

3.1 Ambulatory Patients

The risk of symptomatic VTE in the ambulatory outpatient setting is lower than that in the surgical setting,
and little research had been done to investigate the role of anticoagulant prophylaxis. More recently, three separate randomized controlled trials have evaluated LMWH prophylaxis in patients with metastatic breast cancer, non-small-cell lung cancer, and grades III and IV malignant glioma (Table V) 38–40. No significant difference in VTE or major bleeding was observed between the groups receiving LMWH and placebo. Consequently, routine prophylaxis is not recommended in ambulatory patients. Notably, the risk of VTE and major bleeding appear to vary considerably, depending on the type of tumour.

On the other hand, as many as 20%–30% of patients receiving thalidomide in combination with chemotherapy or high-dose corticosteroids for treatment of multiple myeloma will develop symptomatic VTE 41,42. Although many studies have reported the use of warfarin, aspirin, or LMWH, insufficient reliable data are available to support the efficacy and safety of these agents. Whether lenalidomide is also associated with a high risk of VTE is uncertain. Patients receiving vascular endothelial growth factor inhibitors such as bevacizumab also have an increased risk of arterial and, possibly, venous thrombosis 43,44, but because of an increased bleeding tendency already associated with this treatment, anticoagulation prophylaxis is not recommended.

### 3.2 Hospitalized Patients

No study has been conducted in cancer patients to determine the effects of VTE prophylaxis in the inpatient setting. Large randomized trials that included small numbers of cancer patients have shown that LMWH or fondaparinux can reduce the VTE risk by 50% or more, but whether such results can apply to all hospitalized cancer patients is questionable, because of the higher risks for VTE and major bleeding in those patients 45–47.

### 3.3 Summary: Medical Settings

Based on limited data, routine prophylaxis in the outpatient setting is not recommended, but prophylaxis should be considered in patients receiving thalidomide- or lenalidomide-containing regimens. Anticoagulant prophylaxis for hospitalized patients is warranted based on studies in non-cancer patients, but the risk–benefit ratio is uncertain, given the lack of randomized trial evidence.

### 4. PROPHYLAXIS FOR CENTRAL VENOUS CATHETERS

Central venous catheters are frequently placed in cancer patients, and those devices represent an ongoing thrombogenic focus 48. Many attempts have been made to reduce the incidence of thrombotic complications in this setting, but randomized placebo-con-
Controlled trials have failed to show a reduction in catheter-related thrombosis with thromboprophylaxis. In particular, low-dose warfarin, adjusted-dose warfarin, and prophylactic-dose LMWH do not reduce the 4% risk of symptomatic catheter-related thrombosis (Table VI). For that reason and because of the possibility of increased risk of bleeding, the routine use of prophylaxis in this setting is not recommended.

5. SECONDARY PREVENTION

5.1 Treatment of VTE

Traditional therapy for acute VTE has consisted of initial therapy with unfractionated heparin or LMWH, followed by long-term warfarin therapy. Unfortunately, many cancer patients tolerate warfarin poorly, especially when receiving chemotherapy, with its ensuing gastrointestinal and hematologic side effects. Also, despite maintenance of therapeutic levels of warfarin, one third of patients experience recurrent VTE or treatment-related bleeding.

However, LMWH is clearly superior to warfarin with respect to convenience and efficacy. Given as a once-daily subcutaneous injection, LMWH does not require routine laboratory monitoring, has few drug interactions, and does not rely on gastrointestinal absorption. In the CLOT study, 676 cancer patients with acute DVT or pulmonary embolism were randomized to a 6-month course of traditional therapy with dalteparin followed by warfarin, or to dalteparin alone. To reduce the risk of bleeding in the dalteparin-only group, the dalteparin dose was reduced by 20%–25% after the first month of therapy. After 6 months of treatment, the long-term dalteparin group experienced a 52% reduction in symptomatic recurrent VTE (17% vs. 9%, p = 0.002) as compared with the group continuing on warfarin. In other words, 1 episode of recurrent VTE was prevented for every 13 patients treated. Furthermore, the groups showed no significant difference in bleeding (4% vs. 6% respectively) and no difference in overall mortality.

Based on those results and on supportive findings from other trials (Table VII), the 2004 ACCP guidelines, the ASCO VTE guidelines, and AOM recommend the use of LMWH alone for treatment of VTE in most patients with cancer. Currently, only dalteparin has received regulatory approval for long-term treatment of symptomatic VTE in patients with cancer.

5.2 Recurrent VTE

As mentioned earlier, recurrence of VTE is more common in the setting of warfarin therapy than of LMWH therapy. Unfortunately, the optimal treatment for such patients has yet to be determined. Inferior caval filters have frequently been used in cases of warfarin
failure, but evidence from a large randomized trial primarily in patients without cancer showed that, although the risk of short-term pulmonary embolism is reduced by about three quarters, patients receiving a filter are about twice as likely to develop recurrent VTE. Also, no difference in overall survival was seen. Furthermore, because of the increased risk of recurrent VTE, cancer patients may be at higher risk for development of postphlebitic syndrome.

Based on the foregoing findings, using caval filters as treatment for recurrent VTE cannot be recommended. Rather, changing a warfarin regimen to

| Trial                | Patients (n) | Regimen Control | Duration of treatment | Outcome | VTE Incidences | Major bleeding Incidences |
|----------------------|--------------|-----------------|----------------------|---------|----------------|--------------------------|
| Meyer et al., 2002   | 146          | Enoxaparin 1.5 mg/kg daily | Until DVT, or until line removed | Combined recurrent VTE and hemorrhage | 10.5% 21.1% 0.09 7.0% 16.0% 0.09 |
| Lee et al., 2003     | 672          | Dalteparin 200 IU/kg daily for 1 month, then 150 IU/kg daily for 5 months | As described in “Regimen” | Recurrent VTE | 9.0% 17.0% 0.002 6% 4% 0.27 |
| Deitche et al., 2006 | 122          | Enoxaparin 1 mg/kg twice daily, then 1.0 mg/kg daily or 1.5 mg/kg daily | 5 Days at twice daily, then 6 months | Recurrent VTE | 6.9% 10.0% >0.05 6.5% 2.9% >0.05 |
| Hull et al., 2006    | 200          | Tinzaparin 175 IU/kg daily | 3 Months | Recurrent VTE | 6.0% 10.0% >0.05 7.0% 7.0% >0.05 |

VTE = venous thromboembolism; DVT = deep vein thrombosis; CVC = central venous catheter; INR = international normalized ratio; PE = pulmonary embolism.
LMWH, or increasing the dose of LMWH would be appropriate.

5.3 Duration of Therapy

The optimum duration of anticoagulation in patients with cancer has not been investigated. Extrapolating from populations without cancer, most patients should receive a minimum of 3–6 months of therapy. However, given that cancer represents an ongoing risk factor in this population, the general recommendation is to continue anticoagulation for long as evidence of active malignancy continues. It is of foremost importance that patient care be tailored to suit the individual, with due consideration for quality of life and life expectancy.

5.4 Summary of Secondary Prevention

First-line treatment of VTE in patients with cancer is LMWH for a minimum of 3–6 months. This approach is endorsed by the ACCP, ASCO, AIOM, and the National Comprehensive Cancer Network. The optimum duration is not known, but treatment is usually continued for as long as evidence of malignancy continues.

6. FUTURE DIRECTIONS

The LMWHs have simplified and improved the prevention and treatment of VTE in patients with cancer. Much work must still be done to help identify high-risk patients who would benefit from primary thromboprophylaxis for extended periods after cancer surgery, during medical hospitalization, for prevention of catheter-related thrombosis, and for prevention of VTE associated with highly thrombogenic agents (thalidomide, for example). Also, optimal management in patients with established VTE should be investigated, especially with regard to duration of therapy and the potential role, if any, of invasive strategies such as filter insertion. Lastly, education of physicians to improve the appropriate utilization of prophylaxis in various settings will go a long way toward reducing morbidity and mortality in this vulnerable population.

7. SUMMARY

Recommendations for managing risk of thrombotic events:

- Cancer patients undergoing surgery require VTE prophylaxis, and this prophylaxis can safely be extended in high-risk patients after discharge.
- Medical inpatients with cancer should receive VTE prophylaxis unless absolute contraindications—active bleeding, for instance—are present.
- Prophylaxis for central venous catheters is not recommended.
- Prophylaxis in ambulatory patients is not recommended, except in those who are receiving thalidomide- or lenalidomide-based combination chemotherapy.
- Venous thromboembolism is best treated with LMWH for a minimum of 3–6 months, and treatment can be continued for as long as active cancer is present.
- Inferior caval filters prevent pulmonary embolism in the short term, but they carry a long-term risk of increased VTE and should therefore be avoided when anticoagulation can be administered.

8. REFERENCES

1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809–15.
2. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006;119:60–8.
3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632–4.
4. Sørensen HT, Mellemkjær L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846–50.
5. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neoplastic cancer patients. J Clin Oncol 2006;24:484–90.
6. Hutten BA, Frins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078–83.
7. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484–8.
8. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in U.S. medical centers: success or failure? J Thromb Haemost 2007;5:1610–16.
9. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):S385–400S.
10. Enoxacan Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099–103.
11. McLeod RS, Geerts WH, Sniderman KW, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg 2001;233:438–44.
12. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. on behalf of the PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005;92:1212–20.

13. Bergqvist D, Agnelli G, Cohen AT, et al. on behalf of the ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975–80.

14. Rasmussen MS, Wille–Jorgensen P, Jorgensen LN, et al. Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) following major abdominal surgery for malignancy [abstract 186]. Blood 2003;102:56a.

15. Nurmohamed MT, van Riel AM, Henkens CM, et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996;75:233–8.

16. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998;339:80–5.

17. Goldhaber SZ, Dunn K, Gerhard–Herman M, Park JK, Black PM. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002;122:1933–7.

18. MacDonald RL, Amidei C, Baron J, et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol 2003;59:362–71.

19. Heilmann L, Kruck M, Schindler AE. Prevention of thrombosis in gynecology: double-blind comparison of low molecular weight heparin and unfractionated heparin [German]. Geburtshilfe Frauenheilkd 1989;49:803–7.

20. Clarke–Pearson DL, DeLong E, Synan IS, Coleman RE. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 1990;75:684–9.

21. Fricker JP, Vergnes Y, Schach R, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988;18:561–7.

22. von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997;77:456–61.

23. Heilmann L, von Tempelhoff GF, Kirkpatrick C, Schneider DM, Hommel G, Pollow K. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: efficacy, safety, and follow-up. Clin Appl Thromb Hemost 1998;4:268–73.

24. Haas S, Wolf H, Kakkar AK, Fareed J, Encke A. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. Thromb Haemost 2005;94:814–19.

25. Kakkar AK, Haas S, Wolf H, Encke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost 2005;94:867–71.

26. Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913–30.

27. Agnelli G, Bolis G, Capuzzotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:89–95.

28. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000;89:640–6.

29. Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998;43:1074–9.

30. Oates–Whitehead RM, D’Angelo A, Mol B. Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. Cochrane Database Syst Rev 2003;:CD003679.

31. Wells PS, Lensing AW, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembolism. A meta-analysis. Arch Intern Med 1994;154:67–72.

32. Clarke–Pearson DL, Dodge RK, Synan I, McClelland RC, Maxwell GL. Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression. Obstet Gynecol 2003;101:157–63.

33. Clarke–Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 1993;168:1146–53.

34. Clarke–Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. Gynecol Oncol 1984;18:226–32.

35. Clarke–Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984;63:92–8.

36. Lyman GH, Khorana AA, Falanga A, et al. on behalf of the American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490–505.

37. Mandalà M, Falanga A, Piccioli A, et al. for working group AIOH. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOH). Crit Rev Oncol Hematol 2006;59:194–204.

38. Levine M, Hirsh J, Gent M, et al. Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886–9.

39. Haas S, Kakkar A, Kemkes–Matthes B, et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer—results of the TOPIC studies. J Thromb Haemost 2005;3(suppl 1):OR059.
40. Perry JR, Rogers L, Laperriere N, et al. PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma [abstract]. Proc Am Soc Clin Oncol 2007;25:2011.

41. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319–23.

42. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614–15.

43. Kabbinavar F, Hurwitz HI, Feherenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–5.

44. Marx GM, Steer CB, Harper P, Pavlakis N, Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol 2002;20:1446–8.

45. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389–96.

46. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ on behalf of the PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874–9.

47. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793–800.

48. Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006;24:1404–8.

49. Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063–9.

50. Young AM, Begum G, Billingham LJ, et al. on behalf of the WARP Collaborative Group U.K. WARP—a multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCS) [abstract]. Proc Am Soc Clin Oncol 2005;23:8004.

51. Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:4057–62.

52. Karthaus M, Kretzschmar A, Kröning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289–96.

53. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–53.

54. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729–35.

55. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J on behalf of the ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389–96.

56. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062–72.

57. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):401S–28S.

58. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409–16.

Correspondence to: Agnes Y.Y. Lee, Hamilton Health Sciences Henderson Hospital, 711 Concession Street, Hamilton, Ontario L8V 1C3.

E-mail: alee@mcmaster.ca

* Queen’s University, Kingston, Ontario.
† Department of Medicine, McMaster University, Hamilton, Ontario.